ANI Pharmaceuticals Future Growth
Future criteria checks 3/6
ANI Pharmaceuticals is forecast to grow earnings and revenue by 59% and 8.5% per annum respectively while EPS is expected to grow by 57.1% per annum.
Key information
59.0%
Earnings growth rate
57.1%
EPS growth rate
Pharmaceuticals earnings growth | 19.7% |
Revenue growth rate | 8.5% |
Future return on equity | n/a |
Analyst coverage | Good |
Last updated | 17 Jan 2025 |
Recent future growth updates
Recent updates
ANI Pharmaceuticals, Inc.'s (NASDAQ:ANIP) Prospects Need A Boost To Lift Shares
Dec 18Here's Why ANI Pharmaceuticals (NASDAQ:ANIP) Can Manage Its Debt Responsibly
Nov 09ANI Pharmaceuticals Is Acting Like It Is Being Acquired
Nov 02ANI Pharmaceuticals: A Rare GARP Stock In An Overbought Market
Oct 11There's No Escaping ANI Pharmaceuticals, Inc.'s (NASDAQ:ANIP) Muted Revenues
Sep 10ANI Pharmaceuticals' (NASDAQ:ANIP) Earnings Are Weaker Than They Seem
Aug 14Is ANI Pharmaceuticals (NASDAQ:ANIP) Using Too Much Debt?
Aug 08ANI Pharmaceuticals: Tezruly Just Approved, 2 More NDAs Under Review And Alimera Science Acquisition Could Triple Revenue By 2028
Aug 02Subdued Growth No Barrier To ANI Pharmaceuticals, Inc.'s (NASDAQ:ANIP) Price
Jun 10ANI Pharmaceuticals Is Undervalued, As Royalty Potential Is Overlooked
Jun 10These 4 Measures Indicate That ANI Pharmaceuticals (NASDAQ:ANIP) Is Using Debt Reasonably Well
Feb 17Additional Considerations Required While Assessing ANI Pharmaceuticals' (NASDAQ:ANIP) Strong Earnings
Nov 15Does ANI Pharmaceuticals (NASDAQ:ANIP) Have A Healthy Balance Sheet?
Sep 22Does ANI Pharmaceuticals (NASDAQ:ANIP) Have A Healthy Balance Sheet?
Feb 22We Think ANI Pharmaceuticals (NASDAQ:ANIP) Has A Fair Chunk Of Debt
Oct 28ANI Pharma launches generic Prochlorperazine maleate tablets
Aug 29ANI Pharmaceuticals' generic dexamethasone tablets get FDA approval
Aug 16Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2027 | 811 | 93 | 150 | 205 | 4 |
12/31/2026 | 774 | 58 | 148 | 198 | 5 |
12/31/2025 | 733 | 30 | 95 | 147 | 4 |
12/31/2024 | 599 | -4 | 42 | 97 | 6 |
9/30/2024 | 555 | -9 | 74 | 93 | N/A |
6/30/2024 | 539 | 24 | 94 | 113 | N/A |
3/31/2024 | 517 | 31 | 95 | 116 | N/A |
12/31/2023 | 487 | 15 | 100 | 119 | N/A |
9/30/2023 | 449 | 10 | 53 | 70 | N/A |
6/30/2023 | 401 | -8 | 19 | 41 | N/A |
3/31/2023 | 359 | -28 | -7 | 9 | N/A |
12/31/2022 | 316 | -50 | -48 | -31 | N/A |
9/30/2022 | 283 | -69 | -53 | -39 | N/A |
6/30/2022 | 251 | -65 | -52 | -48 | N/A |
3/31/2022 | 226 | -63 | -61 | -36 | N/A |
12/31/2021 | 216 | -43 | -20 | 3 | N/A |
9/30/2021 | 212 | -22 | -16 | 10 | N/A |
6/30/2021 | 213 | -17 | -17 | 14 | N/A |
3/31/2021 | 213 | -15 | 23 | 34 | N/A |
12/31/2020 | 208 | -23 | -53 | 15 | N/A |
9/30/2020 | 199 | -24 | -42 | 26 | N/A |
6/30/2020 | 198 | -20 | -15 | 49 | N/A |
3/31/2020 | 203 | -1 | -32 | 33 | N/A |
12/31/2019 | 207 | 6 | 18 | 46 | N/A |
9/30/2019 | 216 | 16 | 41 | 68 | N/A |
6/30/2019 | 215 | 17 | 28 | 55 | N/A |
3/31/2019 | 208 | 14 | 30 | 58 | N/A |
12/31/2018 | 202 | 15 | 56 | 67 | N/A |
9/30/2018 | 192 | 0 | -4 | 56 | N/A |
6/30/2018 | 189 | 0 | N/A | 64 | N/A |
3/31/2018 | 187 | 0 | N/A | 56 | N/A |
12/31/2017 | 177 | -1 | N/A | 39 | N/A |
9/30/2017 | 168 | 7 | N/A | 36 | N/A |
6/30/2017 | 158 | 5 | N/A | 20 | N/A |
3/31/2017 | 145 | 4 | N/A | 23 | N/A |
12/31/2016 | 129 | 4 | N/A | 27 | N/A |
9/30/2016 | 108 | 8 | N/A | 20 | N/A |
6/30/2016 | 90 | 10 | N/A | 29 | N/A |
3/31/2016 | 78 | 12 | N/A | 27 | N/A |
12/31/2015 | 76 | 15 | N/A | 17 | N/A |
9/30/2015 | 79 | 33 | N/A | 23 | N/A |
6/30/2015 | 77 | 35 | N/A | 17 | N/A |
3/31/2015 | 64 | 30 | N/A | 18 | N/A |
12/31/2014 | 56 | 29 | N/A | 22 | N/A |
9/30/2014 | 45 | 11 | N/A | 8 | N/A |
6/30/2014 | 36 | 5 | N/A | 3 | N/A |
3/31/2014 | 35 | 1 | N/A | 0 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ANIP is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.6%).
Earnings vs Market: ANIP is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: ANIP is expected to become profitable in the next 3 years.
Revenue vs Market: ANIP's revenue (8.5% per year) is forecast to grow slower than the US market (8.9% per year).
High Growth Revenue: ANIP's revenue (8.5% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if ANIP's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2025/01/31 18:31 |
End of Day Share Price | 2025/01/31 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
ANI Pharmaceuticals, Inc. is covered by 13 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Dewey Steadman | Canaccord Genuity |
Louise Chen | Cantor Fitzgerald & Co. |
Timothy Chiang | Capital One Securities, Inc. |